Glycoprotein Ib alpha Kozak polymorphism in patients presenting with early-onset acute coronary syndrome
Tarih
2018Yazar
Golcuk, EbruYalin, Kivanc
Akdeniz, Cansu Selcan
Teker, Erhan
Teker, Basak
Hancer, Veysel Sabri
Oncul, Aytac
Üst veri
Tüm öğe kaydını gösterÖzet
Introduction: Glycoprotein Ib alpha (GPIb alpha) receptor is the chief molecule responsible for initial platelet adhesion to the subendothelium. A thymidine to cytosine single nucleotide substitution at position -5 from the ATG start codon characterizes the Kozak sequence polymorphism. The Kozak sequence polymorphism may increase the surface expression of GPIb alpha and contribute to thrombogenesis. We evaluated the allele frequencies of GPIb alpha Kozak sequence polymorphism in the Turkish population and examined the relationship between GPIb alpha Kozak sequence polymorphism and early-onset acute coronary syndrome (ACS). Material and methods: This study enrolled 200 patients (122 male, 78 female, mean age: 39 +/- 5 years) and 200 healthy control subjects (110 male, 90 female, 41 +/- 4 years). The patient group was composed of patients admitted to our coronary care unit with early-onset ACS and patients who attended to our cardiology outpatient clinic after hospital discharge with a diagnosis of early-onset ACS. Results: Kozak polymorphism frequencies in patients and control subjects did not differ significantly (23% versus 22.5%, p = 0.812, respectively). In patients who presented with non-ST elevation myocardial infarction (NSTEMI), the frequency of GPIb alpha Kozak polymorphism was borderline significantly higher when compared with patients who presented with ST elevation myocardial infarction (STEMI) (35% vs. 20%, p = 0.05, respectively). Allele frequencies of T and C were calculated to be 0.873 and 0.128. Conclusions: Although the frequency of GPIb alpha Kozak polymorphism did not differ significantly in early-onset ACS patients versus control subjects, Kozak polymorphism frequency was borderline significantly higher in patients who presented with NSTEMI when compared to patients with STEMI.